KR102577824B1 - 티에노피리미딘 유도체 및 의약에서 이의 용도 - Google Patents

티에노피리미딘 유도체 및 의약에서 이의 용도 Download PDF

Info

Publication number
KR102577824B1
KR102577824B1 KR1020197024406A KR20197024406A KR102577824B1 KR 102577824 B1 KR102577824 B1 KR 102577824B1 KR 1020197024406 A KR1020197024406 A KR 1020197024406A KR 20197024406 A KR20197024406 A KR 20197024406A KR 102577824 B1 KR102577824 B1 KR 102577824B1
Authority
KR
South Korea
Prior art keywords
methyl
mixture
mmol
ethyl
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197024406A
Other languages
English (en)
Korean (ko)
Other versions
KR20190110575A (ko
Inventor
완준 탕
신예 양
정 구
천루 리
종위안 장
지푸 완
샤오준 왕
잉준 장
Original Assignee
선샤인 레이크 파르마 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 선샤인 레이크 파르마 컴퍼니 리미티드 filed Critical 선샤인 레이크 파르마 컴퍼니 리미티드
Publication of KR20190110575A publication Critical patent/KR20190110575A/ko
Application granted granted Critical
Publication of KR102577824B1 publication Critical patent/KR102577824B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020197024406A 2017-01-22 2018-01-22 티에노피리미딘 유도체 및 의약에서 이의 용도 Active KR102577824B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017100522753 2017-01-22
CN201710052275 2017-01-22
PCT/CN2018/073581 WO2018133858A1 (en) 2017-01-22 2018-01-22 Thienopyrimidine derivative and use thereof in medicine

Publications (2)

Publication Number Publication Date
KR20190110575A KR20190110575A (ko) 2019-09-30
KR102577824B1 true KR102577824B1 (ko) 2023-09-13

Family

ID=62908330

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197024406A Active KR102577824B1 (ko) 2017-01-22 2018-01-22 티에노피리미딘 유도체 및 의약에서 이의 용도

Country Status (8)

Country Link
US (1) US10759812B2 (https=)
EP (1) EP3571205B1 (https=)
JP (1) JP7046959B2 (https=)
KR (1) KR102577824B1 (https=)
CN (1) CN108341830B (https=)
AU (1) AU2018209006B2 (https=)
CA (1) CA3049816A1 (https=)
WO (1) WO2018133858A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119977993A (zh) 2016-03-02 2025-05-13 吉利德阿波罗公司 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
EP4273132A3 (en) 2017-03-03 2024-01-10 Gilead Sciences, Inc. Processes for preparing acc inhibitors and solid forms thereof
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
WO2019020041A1 (zh) * 2017-07-26 2019-01-31 南京圣和药业股份有限公司 作为acc抑制剂的化合物及其应用
EP3758706A4 (en) 2018-02-28 2021-11-24 The Regents Of The University Of Colorado WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF
CN109810085B (zh) * 2019-04-19 2019-07-19 上海皓元生物医药科技有限公司 Acc抑制剂及其中间体的制备方法
CN111848678A (zh) * 2019-04-30 2020-10-30 正大天晴药业集团股份有限公司 含磷类噻吩并嘧啶衍生物
EP3995498A4 (en) * 2019-07-02 2023-03-01 Sunshine Lake Pharma Co., Ltd. THIENOPYRIMIDI DERIVATIVES WITH STEREO CONFIGURATION AND THEIR USE IN MEDICINE
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
WO2022111517A1 (zh) * 2020-11-24 2022-06-02 正大天晴药业集团股份有限公司 氘修饰的噻吩并吡啶酮化合物
TW202233632A (zh) * 2021-02-07 2022-09-01 大陸商正大天晴藥業集團股份有限公司 噻吩并嘧啶衍生物
CN117126174B (zh) * 2022-05-26 2025-12-05 广东东阳光药业股份有限公司 噻吩并嘧啶类化合物的共晶及其用途
TW202400151A (zh) * 2022-05-26 2024-01-01 大陸商廣東東陽光藥業股份有限公司 噻吩並嘧啶類化合物的晶型及其用途
CN117126175B (zh) * 2022-05-26 2025-12-05 广东东阳光药业股份有限公司 噻吩并嘧啶类化合物的共晶及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013071169A1 (en) 2011-11-11 2013-05-16 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2015007451A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2016112305A1 (en) 2015-01-09 2016-07-14 Nimbus Apollo, Inc. Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19644228A1 (de) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
CA2644996A1 (en) 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
EA201591959A1 (ru) 2013-05-10 2016-03-31 Нимбус Аполло, Инк. Ингибиторы акк и их применение
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
AU2014262547A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
WO2015003881A1 (en) 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
HUE053175T2 (hu) 2015-11-25 2021-06-28 Gilead Apollo Llc ACC-gátló észterek és azok alkalmazása
BR112018009212B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Método para controlar patógenos fúngicos agrícolas
CA3004796C (en) 2015-11-25 2023-11-14 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
EP3380479B1 (en) 2015-11-25 2022-12-07 Gilead Apollo, LLC Triazole acc inhibitors and uses thereof
WO2017147161A1 (en) 2016-02-23 2017-08-31 Raju Mohan Treatment of dermatological disorders or conditions
CN107698603B (zh) 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
CN110431144B (zh) 2017-03-24 2022-08-05 浙江海正药业股份有限公司 氰基取代的杂芳基并嘧啶酮类衍生物及其制备方法和用途
WO2018171698A1 (zh) 2017-03-24 2018-09-27 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物及其制备方法和用途
WO2018228369A1 (zh) 2017-06-15 2018-12-20 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013071169A1 (en) 2011-11-11 2013-05-16 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2015007451A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2016112305A1 (en) 2015-01-09 2016-07-14 Nimbus Apollo, Inc. Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Also Published As

Publication number Publication date
EP3571205B1 (en) 2023-08-30
WO2018133858A1 (en) 2018-07-26
JP7046959B2 (ja) 2022-04-04
EP3571205A4 (en) 2020-06-03
EP3571205A1 (en) 2019-11-27
US10759812B2 (en) 2020-09-01
JP2020505356A (ja) 2020-02-20
CN108341830A (zh) 2018-07-31
KR20190110575A (ko) 2019-09-30
AU2018209006B2 (en) 2021-04-22
CN108341830B (zh) 2021-03-02
CA3049816A1 (en) 2018-07-26
US20190352311A1 (en) 2019-11-21
AU2018209006A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
KR102577824B1 (ko) 티에노피리미딘 유도체 및 의약에서 이의 용도
KR102368298B1 (ko) 질소-함유 트라이사이클릭 화합물, 및 의약에서 이의 용도
RU2678990C1 (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
AU2014287471C1 (en) Fused piperidine amides as modulators of ion channels
JP2021535141A (ja) αｖβ６インテグリンの阻害
KR20160062170A (ko) 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
EP3746448A1 (en) Nitrogenous tricyclic compounds and uses thereof in medicine
EP3897630A1 (en) Thienopyridine inhibitors of ripk2
WO2024057013A1 (en) Nlrp3 modulators
CN105399756B (zh) Btk抑制剂及其用途
WO2022135390A1 (zh) 己酮糖激酶抑制剂及其用途
US12428432B2 (en) Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
WO2018108910A1 (en) Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors
HK40011745A (en) Thienopyrimidine derivative and use thereof in medicine
HK40011745B (en) Thienopyrimidine derivative and use thereof in medicine
KR20240165360A (ko) 에모파밀 결합 단백질 억제제 및 이의 용도
TW202425972A (zh) 三環類化合物及其製備方法和應用
EP4671242A1 (en) PYRIDOPYRIMIDINE DERIVATIVE AND ITS USES
EP1864984A1 (en) Tricyclic spiro compound comprising acyl group bound to nitrogen atom in the ring
WO2024061340A1 (en) Nampt modulators, preparations, and uses thereof
TW202425971A (zh) 三環類化合物及其製備方法和應用
KR20250047747A (ko) 에모파밀 결합 단백질 억제제 및 이의 용도
HK40069535A (en) Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601